vs

Side-by-side financial comparison of Axogen, Inc. (AXGN) and Finwise Bancorp (FINW). Click either name above to swap in a different company.

Axogen, Inc. is the larger business by last-quarter revenue ($61.5M vs $42.7M, roughly 1.4× Finwise Bancorp). Finwise Bancorp runs the higher net margin — 6.4% vs -31.9%, a 38.3% gap on every dollar of revenue. Over the past eight quarters, Finwise Bancorp's revenue compounded faster (47.0% CAGR vs 13.3%).

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

Finwise Bancorp is a U.S.-based financial holding company that operates primarily through its community banking subsidiary. It offers a full suite of retail and commercial financial services, including deposit accounts, personal loans, mortgage products, small business financing, and wealth management solutions, serving local retail consumers and small to medium-sized business clients across its regional operating markets.

AXGN vs FINW — Head-to-Head

Bigger by revenue
AXGN
AXGN
1.4× larger
AXGN
$61.5M
$42.7M
FINW
Higher net margin
FINW
FINW
38.3% more per $
FINW
6.4%
-31.9%
AXGN
Faster 2-yr revenue CAGR
FINW
FINW
Annualised
FINW
47.0%
13.3%
AXGN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AXGN
AXGN
FINW
FINW
Revenue
$61.5M
$42.7M
Net Profit
$-19.6M
$2.7M
Gross Margin
75.2%
Operating Margin
20.2%
Net Margin
-31.9%
6.4%
Revenue YoY
26.6%
Net Profit YoY
-410.8%
EPS (diluted)
$-0.38
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXGN
AXGN
FINW
FINW
Q1 26
$61.5M
$42.7M
Q4 25
$59.9M
$46.9M
Q3 25
$60.1M
$36.7M
Q2 25
$56.7M
$25.1M
Q1 25
$48.6M
$22.1M
Q4 24
$49.4M
$21.1M
Q3 24
$48.6M
$20.8M
Q2 24
$47.9M
$19.8M
Net Profit
AXGN
AXGN
FINW
FINW
Q1 26
$-19.6M
$2.7M
Q4 25
$-13.2M
$3.9M
Q3 25
$708.0K
$4.9M
Q2 25
$579.0K
$4.1M
Q1 25
$-3.8M
$3.2M
Q4 24
$450.0K
$2.8M
Q3 24
$-1.9M
$3.5M
Q2 24
$-1.9M
$3.2M
Gross Margin
AXGN
AXGN
FINW
FINW
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AXGN
AXGN
FINW
FINW
Q1 26
20.2%
Q4 25
-16.3%
11.7%
Q3 25
3.2%
17.5%
Q2 25
3.0%
21.7%
Q1 25
-3.4%
20.1%
Q4 24
4.1%
17.5%
Q3 24
-0.6%
22.2%
Q2 24
-0.9%
21.1%
Net Margin
AXGN
AXGN
FINW
FINW
Q1 26
-31.9%
6.4%
Q4 25
-22.0%
8.4%
Q3 25
1.2%
13.3%
Q2 25
1.0%
16.3%
Q1 25
-7.9%
14.4%
Q4 24
0.9%
13.2%
Q3 24
-3.8%
16.6%
Q2 24
-4.0%
16.1%
EPS (diluted)
AXGN
AXGN
FINW
FINW
Q1 26
$-0.38
$0.20
Q4 25
$-0.28
$0.27
Q3 25
$0.01
$0.34
Q2 25
$0.01
$0.29
Q1 25
$-0.08
$0.23
Q4 24
$-0.00
$0.19
Q3 24
$-0.04
$0.25
Q2 24
$-0.04
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXGN
AXGN
FINW
FINW
Cash + ST InvestmentsLiquidity on hand
$82.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$244.8M
$196.6M
Total Assets
$289.5M
$899.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXGN
AXGN
FINW
FINW
Q1 26
$82.7M
Q4 25
$41.5M
$163.4M
Q3 25
$35.8M
$105.6M
Q2 25
$29.9M
$90.1M
Q1 25
$22.1M
$120.3M
Q4 24
$33.5M
$109.2M
Q3 24
$24.5M
$85.8M
Q2 24
$21.1M
$89.0M
Total Debt
AXGN
AXGN
FINW
FINW
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AXGN
AXGN
FINW
FINW
Q1 26
$244.8M
$196.6M
Q4 25
$128.8M
$193.2M
Q3 25
$120.8M
$187.8M
Q2 25
$112.3M
$182.0M
Q1 25
$105.4M
$177.4M
Q4 24
$103.9M
$173.7M
Q3 24
$99.4M
$170.4M
Q2 24
$95.7M
$165.8M
Total Assets
AXGN
AXGN
FINW
FINW
Q1 26
$289.5M
$899.4M
Q4 25
$221.7M
$977.1M
Q3 25
$216.4M
$899.9M
Q2 25
$205.5M
$842.5M
Q1 25
$196.2M
$804.1M
Q4 24
$203.7M
$746.0M
Q3 24
$192.0M
$683.0M
Q2 24
$188.9M
$617.8M
Debt / Equity
AXGN
AXGN
FINW
FINW
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXGN
AXGN
FINW
FINW
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-1.4M
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXGN
AXGN
FINW
FINW
Q1 26
Q4 25
$3.0M
$-28.4M
Q3 25
$3.2M
$3.5M
Q2 25
$7.7M
$-18.3M
Q1 25
$-13.2M
$-21.6M
Q4 24
$8.7M
$-15.0M
Q3 24
$3.9M
$-9.8M
Q2 24
$4.2M
$-7.6M
Free Cash Flow
AXGN
AXGN
FINW
FINW
Q1 26
$-1.4M
Q4 25
$1.8M
$-28.6M
Q3 25
$1.7M
$3.4M
Q2 25
$7.0M
$-19.8M
Q1 25
$-13.4M
$-23.3M
Q4 24
$8.1M
$-16.1M
Q3 24
$3.3M
$-13.4M
Q2 24
$3.3M
$-7.7M
FCF Margin
AXGN
AXGN
FINW
FINW
Q1 26
-2.3%
Q4 25
3.0%
-61.1%
Q3 25
2.8%
9.4%
Q2 25
12.4%
-79.0%
Q1 25
-27.7%
-105.3%
Q4 24
16.3%
-76.0%
Q3 24
6.8%
-64.3%
Q2 24
6.8%
-38.7%
Capex Intensity
AXGN
AXGN
FINW
FINW
Q1 26
Q4 25
2.1%
0.5%
Q3 25
2.5%
0.1%
Q2 25
1.3%
5.8%
Q1 25
0.5%
7.4%
Q4 24
1.4%
5.1%
Q3 24
1.2%
17.2%
Q2 24
1.9%
0.3%
Cash Conversion
AXGN
AXGN
FINW
FINW
Q1 26
Q4 25
-7.26×
Q3 25
4.55×
0.71×
Q2 25
13.35×
-4.48×
Q1 25
-6.78×
Q4 24
19.41×
-5.37×
Q3 24
-2.84×
Q2 24
-2.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXGN
AXGN

Segment breakdown not available.

FINW
FINW

Net Interest Income$28.1M66%
Noninterest Income$14.6M34%

Related Comparisons